These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 22015995)

  • 1. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.
    Amir AL; Hagedoorn RS; van Luxemburg-Heijs SA; Marijt EW; Kruisselbrink AB; Frederik Falkenburg JH; Heemskerk MH
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):210-9. PubMed ID: 22015995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.
    Rutten CE; van Luxemburg-Heijs SA; Halkes CJ; van Bergen CA; Marijt EW; Oudshoorn M; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):40-8. PubMed ID: 22871556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mismatched human leukocyte antigen class II-restricted CD8⁺ cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation.
    Hirosawa T; Torikai H; Yanagisawa M; Kamei M; Imahashi N; Demachi-Okamura A; Tanimoto M; Shiraishi K; Ito M; Miyamura K; Shibata K; Kikkawa F; Morishima Y; Takahashi T; Emi N; Kuzushima K; Akatsuka Y
    Cancer Sci; 2011 Jul; 102(7):1281-6. PubMed ID: 21466613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone.
    Eljaafari A; Yuruker O; Ferrand C; Farre A; Addey C; Tartelin ML; Thomas X; Tiberghien P; Simpson E; Rigal D; Scott D
    J Immunol; 2013 Jan; 190(1):184-94. PubMed ID: 23225889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
    van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
    Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses.
    Korngold R
    Bone Marrow Transplant; 1992 May; 9(5):355-64. PubMed ID: 1352163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.
    Friedman TM; Jones SC; Statton D; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):224-35. PubMed ID: 15077221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
    Mutis T; Aarts-Riemens T; Verdonck LF
    Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.
    Rutten CE; van Luxemburg-Heijs SA; Griffioen M; Marijt EW; Jedema I; Heemskerk MH; Posthuma EF; Willemze R; Falkenburg JH
    Leukemia; 2008 Jul; 22(7):1387-94. PubMed ID: 18418406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules.
    van Els CA; Zantvoort E; Jacobs N; Bakker A; van Rood JJ; Goulmy E
    Bone Marrow Transplant; 1990 Jun; 5(6):365-72. PubMed ID: 2142441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTL clones isolated from an HLA-Cw-mismatched bone marrow transplant recipient with acute graft-versus-host disease.
    Sugimoto K; Murata M; Terakura S; Naoe T
    J Immunol; 2009 Nov; 183(9):5991-8. PubMed ID: 19812210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
    Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
    Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.